SAN FRANCISCO--(BUSINESS WIRE)--May 16, 2019--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
using its silicon platform, today announced that Emily Leproust, Ph.D.,
CEO and co-founder, will present at the UBS Global Healthcare Conference
on Monday, May 20th at 11:30 a.m. ET.
This presentation will be webcast live and can be accessed by visiting
the “Presentations” page of the investor relations section of the
company's website here.
A replay of the presentation will be archived for a period of 90 days
following the conclusion of the live event.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist makes
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.
Follow us on Twitter
| Facebook
| LinkedIn
| YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005297/en/
Source: Twist Bioscience Corporation
Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com
Media Contact:
Angela Bitting
925- 202-6211
media@twistbioscience.com
